End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
45.65 CNY | +2.93% |
|
+6.88% | +37.29% |
Jul. 07 | Haisco Pharmaceutical to Raise 1.37 Billion Yuan via Share Placement; Shares Slump 5% | MT |
Jul. 02 | Haisco Pharmaceutical Gets Clinical Trial Nod for Muscle Dystrophy Drug | MT |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 2.85 | 0.47 | 1.6 | 2.9 | 2.44 | |||||
Return on Total Capital | 3.85 | 0.58 | 1.88 | 3.29 | 2.71 | |||||
Return On Equity % | 22.98 | 17.93 | 12.94 | 8.09 | 11.14 | |||||
Return on Common Equity | 24.14 | 12.01 | 9.43 | 8.18 | 9.42 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 67.93 | 65.86 | 69.31 | 71.05 | 71.47 | |||||
SG&A Margin | 47.62 | 47.89 | 48.64 | 45.34 | 47.38 | |||||
EBITDA Margin % | 9.36 | 4.79 | 8.25 | 15.05 | 13.39 | |||||
EBITA Margin % | 6.93 | 1.53 | 4.86 | 11.81 | 10.47 | |||||
EBIT Margin % | 6.86 | 1.36 | 4.69 | 8.79 | 7.04 | |||||
Income From Continuing Operations Margin % | 18.06 | 18.66 | 12.99 | 8.81 | 12.53 | |||||
Net Income Margin % | 19.12 | 12.44 | 9.19 | 8.8 | 10.63 | |||||
Net Avail. For Common Margin % | 19.12 | 12.44 | 9.19 | 8.8 | 10.63 | |||||
Normalized Net Income Margin | 10.32 | 3.59 | 3 | 5.04 | 4.21 | |||||
Levered Free Cash Flow Margin | -27.33 | -32.22 | -25.93 | -5.21 | -5.64 | |||||
Unlevered Free Cash Flow Margin | -26.82 | -31.6 | -24.88 | -4.43 | -5 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.66 | 0.55 | 0.55 | 0.53 | 0.55 | |||||
Fixed Assets Turnover | 3.08 | 2.45 | 2.73 | 3.24 | 3.89 | |||||
Receivables Turnover (Average Receivables) | 6.48 | 5.23 | 4.37 | 3.95 | 3.77 | |||||
Inventory Turnover (Average Inventory) | 5.17 | 3.91 | 3.05 | 3.1 | 3.84 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.22 | 1.02 | 1.38 | 1.76 | 1.74 | |||||
Quick Ratio | 1.04 | 0.81 | 1.09 | 1.5 | 1.48 | |||||
Operating Cash Flow to Current Liabilities | 0.12 | 0.02 | 0.06 | 0.3 | 0.28 | |||||
Days Sales Outstanding (Average Receivables) | 56.52 | 69.81 | 83.62 | 92.35 | 97.16 | |||||
Days Outstanding Inventory (Average Inventory) | 70.82 | 93.26 | 119.52 | 117.87 | 95.3 | |||||
Average Days Payable Outstanding | 171.95 | 133.93 | 98.14 | 90.88 | 70.43 | |||||
Cash Conversion Cycle (Average Days) | -44.62 | 29.13 | 105 | 119.34 | 122.03 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 38.7 | 42.78 | 67.38 | 43.32 | 45.46 | |||||
Total Debt / Total Capital | 27.9 | 29.96 | 40.26 | 30.22 | 31.25 | |||||
LT Debt/Equity | 11.73 | 15.87 | 42.28 | 20.75 | 22.11 | |||||
Long-Term Debt / Total Capital | 8.46 | 11.11 | 25.26 | 14.48 | 15.2 | |||||
Total Liabilities / Total Assets | 42.87 | 41.66 | 48.17 | 37.31 | 38.19 | |||||
EBIT / Interest Expense | 8.37 | 1.38 | 2.78 | 6.98 | 6.93 | |||||
EBITDA / Interest Expense | 11.42 | 5.14 | 5.05 | 12.1 | 13.41 | |||||
(EBITDA - Capex) / Interest Expense | -10.63 | -20.74 | -8.7 | 2.85 | 1.77 | |||||
Total Debt / EBITDA | 3.55 | 8.95 | 8.21 | 3.53 | 3.76 | |||||
Net Debt / EBITDA | -0.42 | 4.83 | 5.2 | 0.93 | 1.39 | |||||
Total Debt / (EBITDA - Capex) | -3.81 | -2.22 | -4.77 | 14.97 | 28.55 | |||||
Net Debt / (EBITDA - Capex) | 0.45 | -1.2 | -3.02 | 3.96 | 10.52 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -15.44 | -16.71 | 8.73 | 11.27 | 10.92 | |||||
Gross Profit, 1 Yr. Growth % | -12.64 | -19.25 | 14.43 | 14.06 | 11.57 | |||||
EBITDA, 1 Yr. Growth % | -24.17 | -60.11 | 35.23 | 59.08 | -8.43 | |||||
EBITA, 1 Yr. Growth % | -32.15 | -83.15 | 57.02 | 84.76 | -10.42 | |||||
EBIT, 1 Yr. Growth % | -29.31 | -83.53 | 276.51 | 108.39 | -20.97 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 26.61 | -13.91 | -24.33 | -24.55 | 57.73 | |||||
Net Income, 1 Yr. Growth % | 28.9 | -45.8 | -19.72 | 6.51 | 34 | |||||
Normalized Net Income, 1 Yr. Growth % | 56.53 | -70.99 | -9.25 | 87 | -18.41 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 28.26 | -45.76 | -18.75 | 3.85 | 29.63 | |||||
Accounts Receivable, 1 Yr. Growth % | -9.71 | 16.89 | 41.02 | 9.97 | 21.8 | |||||
Inventory, 1 Yr. Growth % | 18.31 | 16.1 | 33.1 | -18.7 | -3.44 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 8.42 | 0.94 | -5.53 | -7.24 | -7.93 | |||||
Total Assets, 1 Yr. Growth % | -0.77 | 0.17 | 20.79 | 10.01 | 2.19 | |||||
Tangible Book Value, 1 Yr. Growth % | 12.28 | -6.21 | 7.78 | 47.33 | -14.35 | |||||
Common Equity, 1 Yr. Growth % | 22.39 | -2.08 | 6.82 | 37.7 | 0.8 | |||||
Cash From Operations, 1 Yr. Growth % | -73.02 | -82.64 | 164.08 | 375.51 | -1.68 | |||||
Capital Expenditures, 1 Yr. Growth % | 3.27 | 16.82 | -0.4 | -44.16 | 12.7 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 1.86K | 0.47 | -12.68 | -77.63 | 37.71 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 2.74K | 0.49 | -14.61 | -80.2 | 47.84 | |||||
Dividend Per Share, 1 Yr. Growth % | 304.35 | -50.22 | - | - | 107.5 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -1.43 | -16.07 | -4.84 | 9.99 | 11.09 | |||||
Gross Profit, 2 Yr. CAGR % | 8.19 | -16.01 | -3.88 | 14.24 | 12.81 | |||||
EBITDA, 2 Yr. CAGR % | 15.07 | -43.15 | -13.57 | 65.67 | 25.32 | |||||
EBITA, 2 Yr. CAGR % | 15.52 | -64.66 | -23.76 | 106.04 | 34.76 | |||||
EBIT, 2 Yr. CAGR % | 18.3 | -65.88 | -21.26 | 180.11 | 36.05 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 37.6 | 4.4 | -19.29 | -24.43 | 9.09 | |||||
Net Income, 2 Yr. CAGR % | 38.22 | -16.41 | -34.04 | -7.52 | 19.47 | |||||
Normalized Net Income, 2 Yr. CAGR % | 65.85 | -32.61 | -48.69 | 30.27 | 31.6 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 37.96 | -16.59 | -33.62 | -8.14 | 16.02 | |||||
Accounts Receivable, 2 Yr. CAGR % | -19.33 | 2.73 | 28.39 | 24.53 | 15.73 | |||||
Inventory, 2 Yr. CAGR % | 22.71 | 17.2 | 24.31 | 4.02 | -11.4 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 14.49 | 4.61 | -2.35 | -6.39 | -7.58 | |||||
Total Assets, 2 Yr. CAGR % | 6.98 | -0.3 | 10 | 15.29 | 6.03 | |||||
Tangible Book Value, 2 Yr. CAGR % | 14.25 | 2.62 | 0.54 | 26.01 | 12.34 | |||||
Common Equity, 2 Yr. CAGR % | 19.67 | 9.47 | 2.27 | 21.28 | 17.81 | |||||
Cash From Operations, 2 Yr. CAGR % | -33.95 | -78.36 | -32.29 | 254.37 | 116.23 | |||||
Capital Expenditures, 2 Yr. CAGR % | 30.75 | 9.84 | 7.87 | -25.42 | -20.67 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 179.17 | 338.4 | -6.23 | -55.8 | -48.21 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 192.47 | 428.41 | -7.26 | -58.88 | -50.19 | |||||
Dividend Per Share, 2 Yr. CAGR % | 39.92 | 41.88 | - | 3.92 | - | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 21.5 | -6.81 | -8.51 | 0.25 | 10.3 | |||||
Gross Profit, 3 Yr. CAGR % | 23.62 | -1.87 | -6.89 | 1.76 | 13.35 | |||||
EBITDA, 3 Yr. CAGR % | 21.87 | -17.36 | -15.41 | 14.88 | 39.41 | |||||
EBITA, 3 Yr. CAGR % | 25.71 | -37.37 | -24.47 | 16.27 | 60.99 | |||||
EBIT, 3 Yr. CAGR % | 27.95 | -38.69 | -24.04 | 8.91 | 91.01 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 37.93 | 17.69 | -6.22 | -21.08 | -3.43 | |||||
Net Income, 3 Yr. CAGR % | 38.9 | 1.17 | -17.53 | -22.61 | 4.65 | |||||
Normalized Net Income, 3 Yr. CAGR % | 50.32 | -7.25 | -25.58 | -21.04 | 16.27 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 38.93 | 1.06 | -17.32 | -22.94 | 3.03 | |||||
Accounts Receivable, 3 Yr. CAGR % | 2.84 | -8.72 | 14.17 | 21.93 | 23.62 | |||||
Inventory, 3 Yr. CAGR % | 15.27 | 20.47 | 22.28 | 7.9 | 1.47 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 13.61 | 9.78 | 1.11 | -4.01 | -6.91 | |||||
Total Assets, 3 Yr. CAGR % | 6.74 | 4.66 | 6.29 | 10.01 | 10.75 | |||||
Tangible Book Value, 3 Yr. CAGR % | 8.88 | 6.98 | 4.31 | 14.2 | 10.79 | |||||
Common Equity, 3 Yr. CAGR % | 13.49 | 11.93 | 8.58 | 12.93 | 14.03 | |||||
Cash From Operations, 3 Yr. CAGR % | -19.26 | -57.69 | -50.17 | 29.67 | 131.13 | |||||
Capital Expenditures, 3 Yr. CAGR % | 15.23 | 25.93 | 6.31 | -13.38 | -14.42 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 6.92 | 97.05 | 156.22 | -41.84 | -38.36 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 5.5 | 103.25 | 188.03 | -44.57 | -40.39 | |||||
Dividend Per Share, 3 Yr. CAGR % | 9.93 | -0.85 | - | -18.69 | 30.86 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 22.39 | 14.08 | 10.19 | -0.42 | -1.12 | |||||
Gross Profit, 5 Yr. CAGR % | 22.77 | 11.41 | 11.79 | 4.29 | 0.54 | |||||
EBITDA, 5 Yr. CAGR % | -4.44 | -16.26 | 7.64 | 16.49 | 3.93 | |||||
EBITA, 5 Yr. CAGR % | -7.55 | -30.75 | 4.76 | 18.04 | 2.74 | |||||
EBIT, 5 Yr. CAGR % | -7.55 | -32.12 | 5.37 | 12.57 | -4.1 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 10.07 | 3.48 | 11.32 | -1.42 | -0.37 | |||||
Net Income, 5 Yr. CAGR % | 11.33 | -4.86 | 3.12 | -2.4 | -4.35 | |||||
Normalized Net Income, 5 Yr. CAGR % | 6.26 | -14.15 | -2.21 | 6.25 | -6.52 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 11.01 | -4.84 | 3.4 | -2.73 | -5.32 | |||||
Accounts Receivable, 5 Yr. CAGR % | 61.77 | 22.51 | 12.38 | 3.36 | 14.8 | |||||
Inventory, 5 Yr. CAGR % | 23.23 | 16.5 | 18.8 | 13.6 | 7.49 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 11.2 | 9.97 | 6.93 | 3 | -2.46 | |||||
Total Assets, 5 Yr. CAGR % | 9.13 | 5.98 | 8.03 | 8.79 | 6.19 | |||||
Tangible Book Value, 5 Yr. CAGR % | 3.12 | 0.81 | 5.46 | 14.22 | 7.45 | |||||
Common Equity, 5 Yr. CAGR % | 6.12 | 4.76 | 8.86 | 15.58 | 12.18 | |||||
Cash From Operations, 5 Yr. CAGR % | -14.18 | -38.57 | -24.75 | -0.99 | -10.37 | |||||
Capital Expenditures, 5 Yr. CAGR % | 16.23 | 27.55 | 12.23 | 2.13 | -5.43 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 6.31 | -0.14 | 0.98 | 8.42 | 35.17 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 5.62 | -0.26 | -0.27 | 7.31 | 42.75 | |||||
Dividend Per Share, 5 Yr. CAGR % | 8.27 | -16.64 | - | 1.03 | 35.16 |
Select your edition
All financial news and data tailored to specific country editions